RESUMEN
CD44 and CD133 have been considered as cancer stem cell (CSC) markers. Stem cell markers are rarely described in healthy stomach tissues. However, the clinicopathological and prognostic value of CD44 and CD133 in gastric cancer remains controversial. This study investigated the expression of CD44 and CD133 in gastric cancer and non-neoplastic gastric mucosa. We used samples of primary gastric adenocarcinomas (n = 69), metastatic lymph nodes (n = 30), intestinal metaplasia (n = 17), and histologically normal gastric tissues of surgical margins (n = 54). The expression of CD44 and CD133 were studied in samples by immunohistochemistry. Fisher's exact test and a logistic regression model were used in this study. CD44 expression was observed in 12% of samples with intestinal metaplasia, 20% with lymph node metastases, 22% with normal mucosa, to 30% of samples with primary tumors. Most of these positive tumors showed immunostaining in less than 4% of cancerous cells, mainly in the diffuse type. CD133 expression was observed in 7% (intestinal metaplasia) to 46% (normal mucosa). In the positive cases of cancer (24%), in most of them, less than 3% of cells were marked. CD44 and CD133 expression in the histologically normal gastric mucosa was restricted to the deeper regions of the gastric crypts at the level where stem cells and progenitor cells are usually found. CD44 and CD133 expression occurs in few gastric cancer cells, mainly in diffuse carcinomas, and are expressed in histologically normal gastric mucosae. None of the markers are specific for cancer and are also present in intestinal metaplasia and the normal mucosa.
Asunto(s)
Antígeno AC133/biosíntesis , Adenocarcinoma/metabolismo , Receptores de Hialuranos/biosíntesis , Proteínas de Neoplasias/biosíntesis , Células Madre Neoplásicas/metabolismo , Neoplasias Gástricas/metabolismo , Adenocarcinoma/patología , Anciano , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patología , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Células Madre Neoplásicas/patología , Neoplasias Gástricas/patologíaRESUMEN
The envenomation caused by the Bothrops pauloensis snake leads to severe local and systemic effects including acute kidney injury. In this study, we investigated the renal effects by phospholipases A2 (PLA2s), divided into two main subgroups, Asp-49 and Lys-49, isolated from the Bothrops pauloensis snake venom (BpV) in isolated rat kidney system. Both PLA2s (3 µg/mL), added alone to the perfusion system and analyzed for 120 min, had significant effects on isolated rat kidney. Asp-49 reduced Glomerular Filtration Rate (GFR) at 60, 90 and 120 min, and the percentage of total tubular sodium transport (%TNa+) and potassium transport (%TK+) at 120 min. Lys-49 increased Perfusion Pressure (PP) at 120 min and reduced GFR, %TNa+ and the percentage of total tubular chloride transport (%TCl-) at 60, 90 and 120 min. Cytokine release in the kidney tissues were increased with Asp-49 PLA2 (IL-10) and Lys-49 PLA2 (TNF-α, IL-1ß, IL-10). Both increased MPO activity. Asp-49 PLA2 decreased Glutathione (GSH) and increased nitrite levels, while Lys-49 PLA2 increased Malondialdehyde (MDA), GSH and nitrite levels. Histological analysis of the perfused kidneys revealed the presence of glomerular degeneration and atrophy, deposit of proteinaceous material in Bowman's space and intratubular with both PLA2s. These findings indicated that both PLA2s modified the functional parameters in an isolated perfused kidney model with increased oxidative stress and cytokine release. PLA2s are one of the components at high concentration in BpV and our results provide important knowledge about their involvement with the nephrotoxic mechanism.
Asunto(s)
Lesión Renal Aguda/metabolismo , Venenos de Crotálidos/toxicidad , Estrés Oxidativo/efectos de los fármacos , Fosfolipasas A2/metabolismo , Animales , Bothrops , Citocinas , Riñón , Glomérulos Renales , Ratas , Venenos de SerpienteRESUMEN
Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers. Hemorrhagic cystitis (HC) is a common side effect associated with IFO injection, which courses with neutrophil accumulation and affects 6-50% of patients depending on dose intensity. Here, we investigated the role of neutrophils in this inflammatory process. Female Swiss mice (nâ¯=â¯8/group) were injected with saline, IFO (400â¯mg/kg, i.p.), fucoidan (a P- and L-selectins inhibitor, 100â¯mg/kg, i.v.) or IFOâ¯+â¯fucoidan (1-100â¯mg/kg) alone or combined with mesna (80â¯mg/kg i.p.). Another group of mice received anti-Ly6G antibody (500⯵g/mouse, once daily for 2â¯days) for neutrophil depletion before IFO injection. In another experimental setting, animals received granulocyte colony-stimulating factor (G-CSF, 400⯵g/kg), IFO (200â¯mg/kg), G-CSF (25-400⯵g/kg, for 5â¯days)â¯+â¯IFO (200â¯mg/kg, i.p.) or fucoidanâ¯+â¯G-CSFâ¯+â¯IFO. Bladder injury was evaluated 12â¯h after IFO injection. IFO 400â¯mg/kg significantly increased visceral hyperalgesia, bladder edema, hemorrhage, vascular permeability, MPO, IL-1ß and IL-6 tissue levels, and COX-2 immunostaining and expression versus the saline group (Pâ¯<â¯0.05). Conversely, fucoidan (100â¯mg/kg) significantly attenuated these parameters compared to IFO-injected mice (Pâ¯<â¯0.05). Additionally, fucoidan potentiated mesna protective effect when compared with IFOâ¯+â¯mesna group (Pâ¯<â¯0.05). Accordingly, neutrophil depletion with anti-Ly6G reduced inflammatory parameters and bladder injury compared to IFO (Pâ¯<â¯0.05). In contrast, G-CSF enhanced IFO (200â¯mg/kg)-induced HC, which was significantly attenuated by treatment with fucoidan (Pâ¯<â¯0.05). Therefore, neutrophils contribute to the pathogenesis of HC.
Asunto(s)
Antineoplásicos Alquilantes/efectos adversos , Cistitis/inducido químicamente , Hemorragia/inducido químicamente , Ifosfamida/efectos adversos , Infiltración Neutrófila/efectos de los fármacos , Sustancias Protectoras/uso terapéutico , Animales , Cistitis/inmunología , Cistitis/patología , Cistitis/prevención & control , Quimioterapia Combinada , Femenino , Hemorragia/inmunología , Hemorragia/patología , Hemorragia/prevención & control , Mesna/administración & dosificación , Mesna/uso terapéutico , Ratones , Polisacáridos/administración & dosificación , Polisacáridos/uso terapéutico , Sustancias Protectoras/administración & dosificaciónRESUMEN
Irinotecan-based regimens are commonly used for treatment of colorectal cancer, which is limited by mucositis and non-alcoholic steatohepatitis (NASH). Silymarin (SIL) prevents fatty liver disease in the clinical setting and in models of liver damage induced chemically. This study investigated the possible effect of SIL on irinotecan (IRI)-induced NASH. Swiss female mice were injected with saline (SAL 5ml/kg i.p.), IRI (50mg/kg i.p.), SIL (150mg/kg p.o.) or IRI (50mg/kg i.p.)+(SIL 1.5, 15 or 150mg/kg p.o.) thrice/week/7weeks. On the seventh week, blood samples were collected for transaminases assay and livers were collected for histopathology, measurement of the total lipids, malondyadehyde (MDA), non-protein sulfhydryl groups (NPSH), cytokines (IL-1ß, IL 6 and IL-10), 3-nitrotyrosine (N-Tyr) and toll-like receptor 4 (TLR4) immunoexpression, quantification of NF-kB, α-smooth muscle actin (α-SMA), and Escherichia coli 16S rRNA gene (RRS) expression. IRI increased liver transaminases, neutrophil infiltration, lipid accumulation, MDA, IL-1ß and IL-6 levels, N-Tyr and TLR4 immunostaining, NF-kB, α-SMA expression and RRS versus the SAL group (p<0.05). Additionally, SIL (1.5mg/kg) improved these parameters (p<0.05), except neutrophil infiltration and RSS versus the IRI group. Furthermore, the SIL (15mg/kg) only improved the inflammatory parameters, the expression of α-SMA and RRS versus the IRI group (p<0.05). The higher dose of SIL (150mg/kg) was even more deleterious than the intermediate dose. Therefore, silymarin showed a dual effect on liver damage induced by IRI. Hepatoprotection seems to involve the inhibition of oxidative stress and protein nitrosylation, preventing activation of hepatic fibrosis mechanisms.